DaVita (NYSE:DVA) Price Target Raised to $224.00

DaVita (NYSE:DVA) had its target price hoisted by equities research analysts at Barclays from $218.00 to $224.00 in a research report issued to clients and investors on Wednesday, Marketbeat reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s target price indicates a potential downside of 1.83% from the company’s current price.

DVA has been the subject of several other reports. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. UBS Group upped their target price on shares of DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, July 10th. TD Cowen increased their price target on shares of DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a report on Monday, May 11th. Truist Financial raised their price target on shares of DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Finally, Deutsche Bank Aktiengesellschaft raised shares of DaVita from a “hold” rating to a “buy” rating and upped their price objective for the company from $126.00 to $220.00 in a research report on Wednesday, May 6th. Two analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $217.50.

DaVita Price Performance

DaVita stock opened at $228.17 on Wednesday. DaVita has a fifty-two week low of $101.00 and a fifty-two week high of $247.49. The firm has a fifty day moving average price of $219.11 and a two-hundred day moving average price of $175.36. The firm has a market cap of $14.65 billion, a price-to-earnings ratio of 21.17, a P/E/G ratio of 0.77 and a beta of 0.88.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. During the same period in the previous year, the company posted $2.95 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, sell-side analysts expect that DaVita will post 15.07 earnings per share for the current year.

Insiders Place Their Bets

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. The trade was a 12.36% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Joel Ackerman sold 51,471 shares of the firm’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the transaction, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.90% of the stock is owned by insiders.

Institutional Investors Weigh In On DaVita

A number of institutional investors have recently added to or reduced their stakes in DVA. Value Investment Professionals LLC grew its stake in shares of DaVita by 2.0% in the 2nd quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock valued at $556,000 after purchasing an additional 50 shares during the period. Kesler Norman & Wride LLC boosted its stake in DaVita by 0.8% in the 1st quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock valued at $1,048,000 after buying an additional 55 shares in the last quarter. Gen Wealth Partners Inc grew its position in DaVita by 10.0% in the fourth quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock valued at $100,000 after acquiring an additional 80 shares during the period. NewEdge Advisors LLC grew its position in DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after acquiring an additional 88 shares during the period. Finally, Orion Porfolio Solutions LLC raised its stake in DaVita by 4.4% during the fourth quarter. Orion Porfolio Solutions LLC now owns 2,360 shares of the company’s stock worth $268,000 after acquiring an additional 99 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita delivered adjusted EPS of $4.02, exceeding consensus estimates of roughly $3.88–$4.01. Revenue rose 5.2% year over year to $3.554 billion, above the $3.50 billion estimate, while adjusted operating income reached $579 million and free cash flow was $256 million. DaVita Inc. Second Quarter 2026 Results
• Positive Sentiment: Management highlighted continued U.S. dialysis treatment-volume growth, strategic execution, and investments in kidney-care innovation. Earnings increased substantially from $2.95 per share in the prior-year quarter. DaVita Q2 2026 Earnings Call Highlights

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.